|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
6/11/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
-9,375
|
$23.76
|
-62.21%
|
|
6/11/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
9,375
|
$15.75
|
164.62%
|
|
5/30/2013
|
MUTO FREDERICK T
|
Director
|
-10,000
|
$21.96
|
-100.00%
|
|
5/1/2013
|
BENNETT C FRANK
|
SVP, Antisense Research
|
-6,145
|
$22.26
|
-74.44%
|
|
5/1/2013
|
BENNETT C FRANK
|
SVP, Antisense Research
|
6,145
|
$11.12
|
291.23%
|
|
5/1/2013
|
BENNETT C FRANK
|
SVP, Antisense Research
|
-23,800
|
$22.26
|
-91.86%
|
|
5/1/2013
|
BENNETT C FRANK
|
SVP, Antisense Research
|
23,800
|
$6.81
|
1,127.96%
|
|
4/30/2013
|
BENNETT C FRANK
|
SVP, Antisense Research
|
30,000
|
$11.12
|
1,421.80%
|
|
4/30/2013
|
BENNETT C FRANK
|
SVP, Antisense Research
|
-30,000
|
$22.51
|
-93.43%
|
|
4/25/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
18,400
|
$6.81
|
625.64%
|
|
4/25/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
7,454
|
$11.12
|
253.45%
|
|
4/25/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
-18,400
|
$22.50
|
-86.22%
|
|
4/25/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
-7,454
|
$22.50
|
-71.71%
|
|
4/24/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
10,417
|
$15.38
|
3,472.33%
|
|
4/24/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-10,000
|
$22.12
|
-1.20%
|
|
4/24/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
-10,417
|
$22.38
|
-97.20%
|
|
4/24/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
30,000
|
$11.12
|
1,020.06%
|
|
4/24/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
-30,000
|
$22.12
|
-91.07%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
3,900
|
$10.29
|
294.56%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-3,900
|
$22.13
|
-74.66%
|
|
4/23/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
10,000
|
$11.12
|
340.02%
|
|
4/23/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
-10,000
|
$22.10
|
-100.00%
|
|
4/23/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-30,000
|
$22.10
|
-3.47%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-1,800
|
$22.13
|
-57.62%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
1,800
|
$8.00
|
135.95%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-2,700
|
$22.13
|
-67.10%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
6,000
|
$15.38
|
453.17%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
10,660
|
$14.18
|
805.14%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-10,660
|
$22.13
|
-88.95%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
2,260
|
$14.47
|
170.69%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-2,260
|
$22.13
|
-63.06%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
2,700
|
$11.27
|
203.93%
|
|
4/23/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-6,000
|
$22.13
|
-81.92%
|
|
4/22/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
-2,813
|
$21.40
|
-90.36%
|
|
4/22/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
3,000
|
$15.38
|
1,000.00%
|
|
4/22/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
-3,000
|
$21.41
|
-90.91%
|
|
4/22/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
2,000
|
$15.38
|
666.67%
|
|
4/22/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
-2,000
|
$21.43
|
-86.96%
|
|
4/22/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
2,813
|
$15.38
|
937.67%
|
|
4/22/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
-9,843
|
$21.49
|
-97.04%
|
|
4/22/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance & CFO
|
9,843
|
$14.47
|
3,281.00%
|
|
4/22/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
30,000
|
$11.12
|
1,020.06%
|
|
4/22/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
-17,000
|
$21.26
|
-74.91%
|
|
4/22/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
-30,000
|
$20.99
|
-91.07%
|
|
4/22/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
17,000
|
$11.12
|
298.51%
|
|
4/22/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
20,000
|
$7.26
|
1,204.09%
|
|
4/22/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-20,000
|
$20.99
|
-92.33%
|
|
4/22/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-10,000
|
$20.99
|
-1.14%
|
|
4/19/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
30,000
|
$7.26
|
1,806.14%
|
|
4/19/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
-2,500
|
$21.25
|
-30.51%
|
|
4/19/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
2,500
|
$11.12
|
43.90%
|
|
4/19/2013
|
CROOKE STANLEY T
|
Chairman, CEO and President
|
-30,000
|
$20.01
|
-94.75%
|
|
4/19/2013
|
Geary Richard S
|
SVP, Development
|
2,042
|
$11.12
|
48.00%
|
|
4/19/2013
|
Geary Richard S
|
SVP, Development
|
-2,042
|
$20.80
|
-32.43%
|
|
4/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-5,000
|
$21.01
|
-79.06%
|
|
4/19/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
-30,000
|
$20.01
|
-91.07%
|
|
4/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-3,000
|
$20.25
|
-69.38%
|
|
4/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
3,000
|
$15.38
|
226.59%
|
|
4/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
1,000
|
$14.18
|
75.53%
|
|
4/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-1,000
|
$19.60
|
-43.03%
|
|
4/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
5,000
|
$15.38
|
377.64%
|
|
4/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
-6,000
|
$20.01
|
-81.92%
|
|
4/19/2013
|
O'NEIL PATRICK R.
|
SVP, Legal & General Counsel
|
6,000
|
$14.47
|
453.17%
|
|
4/19/2013
|
PARSHALL B LYNNE
|
COO, Secretary
|
30,000
|
$7.26
|
1,020.06%
|
|
4/12/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
-4,330
|
$19.62
|
-76.58%
|
|
4/12/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
1,130
|
$14.47
|
85.35%
|
|
4/12/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
-1,130
|
$19.60
|
-46.05%
|
|
4/12/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
4,330
|
$14.18
|
327.04%
|
|
4/11/2013
|
Geary Richard S
|
Sr VP, Development
|
-7,000
|
$19.52
|
-62.20%
|
|
4/11/2013
|
Geary Richard S
|
Sr VP, Development
|
7,000
|
$11.12
|
164.55%
|
|
3/21/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
9,000
|
$14.18
|
679.76%
|
|
3/21/2013
|
Geary Richard S
|
Sr VP, Development
|
-1,000
|
$19.50
|
-19.03%
|
|
3/21/2013
|
Geary Richard S
|
Sr VP, Development
|
1,000
|
$11.12
|
23.51%
|
|
3/21/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
-9,000
|
$19.26
|
-87.18%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
-3,750
|
$18.00
|
-100.00%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
173
|
$5.93
|
173.00%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
-4,166
|
$18.00
|
-97.66%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
4,166
|
$9.77
|
4,166.00%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
-4,167
|
$18.00
|
-100.00%
|
|
3/20/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance and CFO
|
9,584
|
$11.12
|
3,194.67%
|
|
3/20/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance and CFO
|
-9,584
|
$18.13
|
-96.96%
|
|
3/20/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance and CFO
|
4,792
|
$11.12
|
1,597.33%
|
|
3/20/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance and CFO
|
-4,792
|
$18.13
|
-94.11%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
-2,500
|
$18.00
|
-100.00%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
-1,250
|
$18.00
|
-100.00%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
-174
|
$18.00
|
-100.00%
|
|
3/20/2013
|
KLEIN JOSEPH III
|
Director
|
-173
|
$18.00
|
-63.37%
|
|
3/19/2013
|
KLEIN JOSEPH III
|
Director
|
-3,727
|
$18.00
|
-100.00%
|
|
3/19/2013
|
KLEIN JOSEPH III
|
Director
|
-3,726
|
$18.00
|
-100.00%
|
|
3/13/2013
|
KLEIN JOSEPH III
|
Director
|
-6,667
|
$18.01
|
-100.00%
|
|
3/13/2013
|
KLEIN JOSEPH III
|
Director
|
-6,666
|
$18.01
|
-98.52%
|
|
3/13/2013
|
KLEIN JOSEPH III
|
Director
|
-266
|
$18.01
|
-100.00%
|
|
3/13/2013
|
KLEIN JOSEPH III
|
Director
|
-268
|
$18.01
|
-72.83%
|
|
3/13/2013
|
KLEIN JOSEPH III
|
Director
|
268
|
$5.93
|
268.00%
|
|
3/13/2013
|
KLEIN JOSEPH III
|
Director
|
6,666
|
$5.17
|
6,666.00%
|
|
3/5/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
-18,240
|
$16.86
|
-76.21%
|
|
3/5/2013
|
Monia Brett P
|
SVP, Antisense Drug Discovery
|
18,240
|
$6.81
|
320.28%
|
|
3/5/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance and CFO
|
-5,040
|
$16.86
|
-94.38%
|
|
3/5/2013
|
HOUGEN ELIZABETH L
|
SVP, Finance and CFO
|
5,040
|
$6.81
|
1,680.00%
|
|
3/4/2013
|
O'NEIL PATRICK R.
|
SVP, Legal and General Counsel
|
10,350
|
$11.27
|
781.72%
|